Abstract: This disclosure relates to a circulating tumour cell typing and identification kit, comprising a capture probe, an amplification probe, and a labeled probe for each marker gene mRNA, wherein the marker gene mRNA comprises the following two types: at least two epithelial cell marker gene mRNAs selected from the group consisting of EPCAM, E-cadherin, CEA, KRT5, KRT7, KRT17, and KRT20 mRNAs; and, at least two mesenchymal cell marker gene mRNAs selected from the group consisting of VIMENTIN, N-cadherin, TWIST1, AKT2, ZEB2, ZEB1, FOXC1, FOXC2, SNAI1 and SNAI2 mRNAs. This disclosure prevents false-positive results caused by, for example, possible presence of a number of non-neoplastic epithelial cells in peripheral blood, introduction of normal epithelial cells during blood sampling, and the like.

Abstract: This disclosure relates to a circulating tumour cell typing and identification kit, comprising a capture probe, an amplification probe, and a labeled probe for each marker gene mRNA, wherein the marker gene mRNA comprises the following two types: at least two epithelial cell marker gene mRNAs selected from the group consisting of EPCAM, E-cadherin, CEA, KRT5, KRT7, KRT17, and KRT20 mRNAs; and, at least two mesenchymal cell marker gene mRNAs selected from the group consisting of VIMENTIN, N-cadherin, TWIST1, AKT2, ZEB2, ZEB1, FOXC1, FOXC2, SNAI1 and SNAI2 mRNAs. This disclosure prevents false-positive results caused by, for example, possible presence of a number of non-neoplastic epithelial cells in peripheral blood, introduction of normal epithelial cells during blood sampling, and the like.

Abstract: Probes, liquid chips and method for detecting BRAF exon 15 mutations are disclosed. The liquid chip for detecting BRAF exon 15 mutations comprises: microspheres coupled with amino-substituted wild-type probes specific for exon 15, and microspheres coupled with amino-substituted mutant-type probes specific for exon 15; primers for amplifying target sequences enriched for mutant alleles of BRAF exons 15 and biotin-labeled at the terminal. The method of this invention is rapid and accurate in detection, and easy in operation, whereby the detection efficiency is greatly improved.

Abstract: Probes, liquid phase chips and methods for detecting PIK3CA gene mutations are provided, wherein the liquid chips for detecting PIK3CA gene mutations mainly comprise: microspheres coupled with probes; primers used for amplifying target sequences with exon 9 and/or exon 20. The liquid chips and methods for detecting PIK3CA gene mutations are useful for detecting the sites containing mutations of the PIK3CA gene with relatively high frequency simultaneously, and also are useful for detecting the exon 9 and exon 20 separately or simultaneously. The detection methods have identical reaction conditions of detection, good specificity of detection, high sensitivity, above 90% accuracy, and short time of detection.

Abstract: Nucleic acid probes for detecting kRas gene mutations, liquid chips and detection methods thereof are provided. The liquid chips for detecting kRas gene mutations comprise: microspheres coupled with wild-type and mutant-type probes, each of which is amino-substituted at 5?-terminal, specific for kRas codons 12, 13 and/or 61, and primers for amplifying the target sequence biotin-labeled at the terminal which are enriched with mutant alleles of kRas codons 12, 13 and/or 61 to be detected. The detection methods are rapid and accurate, and the processes of the methods are easy to perform. The liquid chip can be used to detect mutations of kRas as assistance to early diagnosis of pancreatic cancer, and can be used to prognose efficiency of the molecular targeted therapy to choose right medicine accurately clinically and avoiding economic loss and time loss caused by unnecessary treatment.